ADMA Biologics, a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment of immune deficiencies and prevention of certain infectious diseases, has acquired certain manufacturing and therapy-related assets from Biotest Pharmaceuticals, a wholly-owned subsidiary of Biotest AG. ADMA’s lead product candidate, RI-002, is manufactured at Biotest’s facility in Boca Raton, FL. ADMA has been working closely with...